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Abstract
Background/Aim. The cell line C6 is a continuous cell line
of rat glioma and, as a transplantable line, is frequently used
for induction into in vivo model of primary brain tumor. It is
believed that, pursuant to its histological traits and biological
behavior, this experimental tumor corresponds to human ana-
plastic astrocytoma of grade II/III, which is characterized by
proliferative and invasive potency, and marked cell differentia-
tion. The aim of this study was to determine macroscopic
analysis of rat brain with implanted tumor during tumorigene-
sis, histological features of tumor cells of induced brain tumor
and markers of proliferation (proliferation cell nuclear antigen
– PCNA, cytokeratin – CK 19) and differentiation (glial fibril-
lary acidic protein –GFAP) in rat brain with implanted tumor.
Methods. To determine histological structure of the brain
with implanted C6 cells, we used brain sections stained for
hematoxylin-eosin or kresyl violet, whereas other sections
were immunohistochemically stained for GFAP, CK 19 and
PCNA.  Results. A statistically significant difference in
weights of the left and right brain hemispheres with implanted
tumors during tumorigenesis in as soon as 7 days from the day
of inducing tumors was revealed. The tumor was of cellular
type, with distinct pleomorphism of cells and frequent hyper-
chromasia of the nucleus. Immunohistochemical staining for
PCNA revealed a significant number of positive cells on the
days 7, 14 and 21 day following the implantation of C6 cells.
CK 19 positive cells were present in both brain hemispheres,
and numerous GFAP positive astrocytes were found around
the puncture lesion. Conclusions. Within the experimental
conditions of the present research, C6 glioma did not demon-
strate any relevant deviations concerning development, clinical
symptomatology and macroscopic anatomy relative to those
already described in the literature.
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Apstrakt
Uvod/Cilj. üelijska linija C6 predstavlja kontinuiranu ýelijsku
liniju glioma pacova i kao transplantabilna linija, ÿesto se kori-
sti za indukciju in vivo modela primarnog moždanog tumora.
Smatra se da po histološkim osobinama ili biološkom pona-
šanju ovaj eksperimentalni tumor odgovara humanom ana-
plastiÿnom astrocitomu gradusa II/III, koji  karakteriše proli-
ferativni i invazivni potencijal, kao i izražena ýelijska diferen-
cijacija. Cilj ovog rada bio je da se odrede: makroskopska
analiza mozgova pacova sa implantiranim tumorom u toku
tumorogeneze, histološke karakteristike tumorskih ýelija in-
dukovanog moždanog tumora i markeri proliferacije (prolife-
rativni ýelijski nuklearni antigen – PCNA, citokeratin – CK
19) i diferencijacije (glialni fibrilatni kiseli protein – GFKP) u
mozgu pacova sa implantiranim tumorom. Metode. Za od-
reĀivanje histološke graĀe mozga sa implantiranim C6 ýelija-
ma korišýeni su iseÿci mozga obojeni hematoksilin-eozinom
ili krezil violet bojom, dok su drugi iseÿci imunohistohemijski
obojeni na GFKP, citokeratin 19 i PCNA. Rezultati. Utvr-
Āeno je da postoji statistiÿki znaÿajna razlika u težini izmeĀu
leve i desne hemisfere mozgova sa implantiranim tumorima u
toku tumorogeneze veý 7 dana od indukcije tumora. Tumor
je bio celularnog tipa, sa izraženim pleomorfizmom ýelija i ÿe-
stom hiperhromazijom nukleusa. Imunohistohemijsko boje-
nje na PCNA pokazalo je veliki broj pozitivnih ýelija posle 7,
14, i 21 dan od implantacije C6 ýelija. üelije pozitivne na CK
19 bile su prisutne u obe hemisfere mozga, a brojni GFAP
pozitivni astrociti naĀeni su oko mesta ubodne lezije. Zaklju-
ÿak. U eksperimentalnim uslovima ove studije gliom C6 nije
pokazao znaÿajnija odstupanja u smislu razvoja, kliniÿke sim-
ptomatologije i makroskopske anatomije od one koja je veý
opisana u literaturi.
Kljuÿne reÿi:
gliom; pacovi; bolest, modeli na životinjama;
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Introduction
One of the most frequently used tumor cell lines in vitro
in neurobiology are C6 cells. The C6 cell line is a continuous
cell line of rat glioma, which has been originally induced in
Wistar rats by intravenous application of N-methyl ni-
trosourea 
1. Given that it is also a transplantable line, it is
frequently used for in vivo induction of primary brain tumor
model 
2. It is believed that, pursuant to its histological traits
and biological behavior, this experimental tumor corresponds
to human anaplastic astrocytoma of grade II/III 
3.
Clarification of biochemical pathways for the progression
of cell cycle made it possible to identify the PCNA antigen
(proliferating cell nuclear antigen), which made a practical tool
as a tumor proliferation marker. The PCNA, a member of the
cyclin family, is a nuclear protein which attaches to DNA delta
polimerase and is necessary for replication of DNA 
4. Its pres-
ence is related to late G1 and S phases of cell cycle. Anti-
PCNA antibodies are commercially available, and used to de-
termine the proliferative potential of CNS tumor 
5. This anti-
gen proved to be a more reliable and accurate marker of tumor
cell proliferation relative to the mitotic index.
Cytokeratin 19 (CK 19) is an acidic protein that makes
a part of epithelial cell structure. It contributes to the cell re-
sistance, transduction of signals and regulation of cell mi-
gration and invasion 
6. As an intermediate filament excreted
by epithelial cells, it is used as a marker for the differentia-
tion of epithelial cells.
Glial fibrillary acidic protein (GFAP) is the key con-
stituent of intermediate filaments with normal, reactive and
neoplastic astrocytes. It is considered that the expression of
GFAP in astrocytoma is in correlation with cell differentia-
tion, and in inverse relation with proliferative potential 
7. The
exception is protoplasmic astrocytoma, which displays either
a minimal GFAP immunoreactivity or none at all 
8. Immu-
nohistochemical detection of GFAP is vital in neuropa-
thological research of astrocytoma 
9.
The experience so far tells us that when compared with
similar experimental models C6 cells grow more homogene-
ous intracerebrally and imitate the growth of human glioma
to a greater extent 
10, which was the basis for decision to
monitor the said markers in the experimental rat glioma.
The aim of the research was to determine: macroscopic
analysis of brains having implanted tumor during the tumori-
genesis; histological traits of tumor cells of an induced brain
tumor (animal model); PCNA, CK 19 and GFAP in rat brain
having implanted tumor.
Methods
C6 cells were used to induce experimental brain tumor.
C6 cells were maintained in culture on nutrient medium,
Dulbecco Modified Eagle Medium (DMEM), with added
10% v/v inactivated fetal calf serum (FCS) and mixture of
antibiotics (penicilin-100 U/mL, streptomicin-100 g/mL
and amphotericin B-25 g/mL). Flasks with cells were kept
in humid environment with present 5% CO2 at 37qC. In order
to prepare cells for cerebral implantation, they were submit-
ted to trypsinization, centrifugation, rinsing and re-
suspending in phosphate buffered saline (PBS).
Cerebral implantation of C6 cells was performed on
Wistar male rats weighing on average 242 grams. They were
firstly anesthetized by intraperitoneal application of sodium
thiopental (50 mg/kg) and thereafter fixed in place on a
wooden platform in the proper position. Next, the skin of
head was depilated and disinfected. A scalpel was used for
skin incision and subcutaneous tissue along the midline, in
anteroposterior direction, for 1.5–2 cm. After removing the
periosteum, craniotomy was performed using a dental drill,
in the right-hand frontopariental region of the skull, 4 mm to
the right and 2–3 mm above the coronary satura. Using the
Hamilton syringe, suspension of C6 cells (4 u 10
6 cells/10 nL
PBS) was injected into the right brain hemisphere to the
depth of 5 mm. Thereafter, the incision was shut by suture,
and animals were placed into individual cages to recover. It
took 21–25 days to develop the tumor in animals.
The second group of animals underwent the identical
procedure, except that instead of C6 cells suspension, they
were injected the same volume of media for making suspen-
sion (the group of ostensibly operated animals). Both groups
of animals were nourished pursuant to standard hygienic and
dietary regime up to the beginning of experiment.
After a light ether anesthesia, the animals were sacri-
ficed by means of decapitation; the brains were carefully
taken out and examined for macroscopic presence of tumor.
The hemispheres were divided, weighed separately, and
subjected to further procedure.
After sacrifying animals with implanted C6 cells, their
brains were taken for histological analysis. The brain tissue
was fixed in 4% paraformaldehyde (in phosphate puffer, pH
7,4) for 2–3 days at 4qC, and thereafter was performed cryo-
protection in 30% Sukrozi and PBS for 2–3 days at 4qC.
Then the tissue was sliced by cryotome (Reichart) at the
temperature of -25qC. The section thick 14 nm were mounted
on the previously jelly-coated microscopic plates and stored
at -20qC. The sections were stained for hematoxylin-eosin or
kresyl violet in order to visualize the overall histological
structure of brain implanted with C6 cells, whereas other
ones were immunohistochemically stained for GFAP, CK 19
and PCNA.
The ABC (avidin-biotin-peroxidase rena complex)
method
 11 was used to determine immunoreactivity as fol-
lows: rinsing the sections in PBS; blocking the endogen per-
oxidase by incubation of sections in 0.3% hydrogen peroxide
in methanol; incubation with 20% normal goat serum to
block the non-specified associating of secondary antibodies;
incubation with solution of primary antibodies (polyclonal
anti-GFAP ICN Pharmaceuticals 1:500; monoclonal anti-CK
19 ICN Pharmaceuticals 1:100; monoclonal anti-PCNA
Boehringer Manheim 1:100) in PBS with 1% BSA (bovine
serum albumin), 1h; incubation with appropriate secondary
antibody conjugated by biotin, 1h; incubation with avidin-
biotin-peroxidase complex, 30 min; and stained reaction -
diaminobenzidine (DAB)-H2O2,5 min.
In between all incubations the rinsing in PBS was per-
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out primary antibodies were used. All reactions took place at
room temperature.
The DMEM nutrient medium, FCS, ready-made mix-
tures of antibiotics and antimycotics, solution for trypsiniza-
tion, all other standard chemicals for maintaining cell cul-
tures, and plastic disposable containers, were given by ICN
Pharmaceuticals, Costa Mesa, USA. The C6 rat glioma cells
were given by Prof. Dr. Stukalov (Institute for Molecular
Genetics, Moscow, Russia).
Male Wistar rats were bred in the Vivarium of the
Center for Biomedical Research, ICN Galenika Institute.
Results
Macroscopic analysis of tumor
The presence of tumor was often accompanied by
edema, although the tumor itself was not always macro-
scopically visible. Macroscopic tumors were only visible in
20% of cases, as a bump in the right hemisphere with a 2 mm
diameter. Measuring of the right and left hemispheres of
brains with implanted tumors during the tumorigenesis re-
vealed a statistically significant difference in weight between
the left and the right hemispheres in as soon as 7 days after
the tumor incubation event (Table 1).
Microscopic structure of C6 rat glioma
Histological preparations stained by hematoxylin-eosin
had a clear place of puncture lesion in the right brain hemi-
sphere, however the tumor mass itself could rarely be no-
ticed, due the tendency of C6 cells’ to infiltrative growth.
The tumor was of cellular type, with a marked pleomorphism
of cells and a frequent hyperchromasia of the nucleus.
Immunohistochemical staining for PCNA revealed nu-
merous PCNA positive cells in the right brain hemisphere
migrating along the white matter, and also appearing in the
left hemisphere (Figure 1).
The proliferation rate index (number of positive C6
cells relative to all implanted cells) could not be determined,
so that the monitoring of this index over time was not possi-
ble. However, a significant number of positive cells were
noticed on the days 7, 14, and 21 after the implementation of
C6 cells, meaning that these cells are still proliferating be-
yond the day 21.
Immunohistochemical staining for cytokeratin 19 re-
vealed numerous CK 19 positive cells in both hemispheres of
the brain (Figure 2).
The preliminary results showed that all C6 cells in vitro
were CK 19 positive. A significantly higher number of cells
were found in the right hemisphere, where C6 cells had been
Table 1
Weights of the right and left hemispheres of rat brains with C6 tumor
Brain weights (mg) Days after
implanting C6 cells right hemisphere left hemisphere
7 702.2 ± 71.4* 603.7 ± 20.2
14 620.0 ± 36.6 622.6 ± 82.5
21 592.6 ± 33.7 598.0 ± 20.2
The results are given as an average value ± standard deviation; * p < 0.01.
A.
B.
Fig. 1 – Immunohistochemical staining for proliferating cell
nuclear antigen (PCNA), ABC method and contrast staining
for krezyl-violet.
A) PCNA positive nuclei of C6 cells in the right brain hemisphere 14 days af-
ter the implantation (u 1,000). B) The number of PCNA – positive C6 cells in
the left hemisphere is substantially lower (u 1,000).
A.
B.
Fig. 2 – Immunohistochemical staining for cytokeratin 19,
ABC method and contrast staining for krezyl-violet.
A) Numerous cytokeratin 19–positive cells in the right brain hemisphere 7
days after C6 cells implantation (u 400). B) Individual cytokeratin 19–posi-
tive cells in the counter lateral hemisphere indicate that C6 cells infiltrated
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implanted, than in the left hemisphere, where they arrived by
means of migration. In the control brain sections of normal
rats, CK 19 positive cells were found only in the capillary
endothelium.
Immunohistochemical reaction with anti-GFAP anti-
bodies revealed numerous GFAP positive astrocytes that
were found close to the puncture lesion spot. These astro-
cytes showed traits of reactive glia, cells swelling, increase
in the number and length of extensions (Figure 3).
A.
B.
Fig. 3 – Immunohistochemical staining for glial fibrillary
acidis protein (GFAP), ABC method.
A) Numerous reactive GFAP–positive astrocytes close to the point of C6 cells
implantation (u 400). B) Counter lateral hemisphere – only a small number of
normal astrocytes were noticed (u 400).
Implanted C6 cells were not GFAP positive. In vitro,
C6 cells also did not contain GFAP marker of mature glial
phenotype.
Discussion
This study examined experimental brain tumors macro-
scopically, histologically and immunohistochemically for the
presence of proliferation (PCNA) and differentiations (GFAP
and CK 19) cell markers.
The study used animal model of primary brain tumor.
C6 rat glioma cells are commonly used as glioma cells model
for in vitro and in vivo researches related to tumor cells biol-
ogy 
12. The C6 glioma cell line has originally been induced
on Wistar rats bred by random mating, by means of exposing
them to N,Nƍ-nitro-methylurea 
2; once injected into rat
brain 
13, it proved by its attributes to be morphologically
similar to human malignant glioma. A glioma, a tumor on
central nervous system that arise from glial cells, primarily
occurs in the brain, and comprise more than 70% of all brain
tumors. They are histologically malignant 
14 and their typical
hallmark is cell proliferation 
15.
It is considered that C6 glioma is analogous to human
glioma of II/III malignancy degree. This study used animals
in which tumor had been developing for 21–25 days, unlike
other authors who used this model, however with tumor de-
velopment lasting for 10–11 days 
16, 14 days 
17, or 11–21
days 
18 following the cerebral implantation of C6 cells.
While measuring the left and the right hemispheres of
brains with implanted tumor, a difference was observed in
weights of the left and the right hemispheres on the day 7 of
tumorigenesis, indicating that glioma cells display invasive
ability during active division of glioma cells.
As a marker of cell proliferation, PCNA was moni-
tored immunohistochemically in rat brain having implanted
tumor. It was observed that numerous PCNA positive cells
were located not only close to the spot of C6 cells imple-
mentation, but also in the opposite hemisphere, which sup-
ports the migration of C6 cells and their infiltration
throughout the brain.
The C6 cells are known to migrate away from the site of
implantation and infiltrate the adjacent regions of the brain 
10.
Quantification of immunohistochemically stained cells was
not possible, given the huge number of implanted cells (4 mil-
lion), so that monitoring of the increase in number of cells
during tumorigenesis was not possible. However, as soon as 7
days after implementation of C6 cells, a large number of
PCNA positive cells could be observed in both brain hemi-
spheres, which indicating their intensive proliferation.
Immunohistochemical staining for CK 19, an intermedi-
ate filament found in C6 cells in vitro, also showed numerous
positive cells not only at the place of C6 cells implantation, but
also in the opposite hemisphere. The control sections of nor-
mal brain showed no CK 19 positive glial cells or neurons.
Previous analysis of histological preparations to GFAP
revealed a similar morphology of C6 rat glioma and human
glioblastoma, formation of glial edge at the glioma periph-
ery, consisting of GFAP-positive reactive astrocytes. As-
trogliosis was monitored until death of animal (28th day) 
19,
(30th day) 
20. Reactive astrocytes with multiple processes en-
circled not only the primary focus of glioma but also any
other place of tumor invasion into the nerve tissue 
19, 20.
In addition, the injection of radio-tagged monoclonal
antibodies on GFAP model of C6 glioma on rats has indi-
cated their accumulation in tumors. Concentration of anti-
bodies was considerably higher in the tumor-affected hemi-
sphere when compared with the unaffected hemisphere 
21.
In this study, the immunohistochemical determination
of GFAP revealed that tumor cells do not contain this marker
of mature glial phenotype. The C6 cells in culture are also
characterized by the absence of GFAP 
1, and they also retain
this property after implantation and inducing of brain tumor
in vivo. Having that said, around the area of puncture lesion
inflicted during implantation of C6 cells were discernable
numerous reactive astrocytes, which were particularly GFAP
positive.
Within the experimental conditions of this study, C6
glioma did not reveal any noteworthy deviations in terms of
development, clinical symptomatology and macroscopic
anatomy other than those already described in literature 
2, 22.Strana 832 VOJNOSANITETSKI PREGLED Volumen 71, Broj 9
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Conclusion
Macroscopic analysis of C6 rat glioma revealed inva-
sive ability of glioma cells displayed during active division
of glioma cells. Histological preparations of rat brain with
C6 glioma clearly displayed puncture lesion in the right
brain hemisphere, but the tumor mass could rarely be no-
ticed. Microscopic analysis of C6 rat glioma showed the
tumor to be of cellular type, with distinct polymorphism of
cells and frequent hyperchromasia of nucleus. Cell prolif-
eration marker PCNA was identified immunohistochemi-
cally in C6 cells in both hemispheres of the brain, indicat-
ing the proliferative and invasive potential of cells. C6 cells
positive to CK 19 were found in both hemispheres of the
brain, thus further supporting migration of these cells. Nu-
merous GFAP positive astrocytes were found around the
place of puncture lesion. Implanted cells were not GFAP
positive.
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